Table 3.
In vitro anti-leishmanial activity and cytotoxicity of compounds selected by virtual screening.
| Compound | Leishmania donovani LV9 Axenic Amastigotes IC50 ± SD (μM) | Leishmania donovani LV9 Intramacrophage Amastigotes IC50 ± SD (μM) | Cytotoxicity on RAW 264.7 Macrophages CC50 ± SD (μM) | SI = CC50/IC50 Intramacro. Amas. |
|---|---|---|---|---|
| 2 | 1.09 ± 0.12 | 2.18 ± 0.12 | 4.87 ± 0.39 | 2.2 |
| 3 | >100 | >100 | >100 | / |
| 4 | 12.50 ± 0.62 | 11.22 ± 0.62 | 16.34 ± 1.42 | 1.4 |
| 5 | 61.52 ± 5.99 | 55.22 ± 4.77 | > 100 | >1.8 |
| 1 | 11.89 ± 1.87 | 6.25 ± 1.89 | 13.86 ± 2.11 | 2.2 |
| 8 | 59.86 ± 6.45 | 51.26 ± 4.35 | >100 | >1.9 |
| 7 | 51.21 ± 4.98 | 47.24 ± 3.12 | >100 | >2.1 |
| 12 | >100 | >100 | >100 | / |
| AmB | 0.20 ± 0.08 | 0.11 ± 0.09 | 5.36 ± 0.52 | 48.7 |